The Effect of Lansoprazole in Combination With Ecabet Sodium for Gastroesophageal Reflux Disease
Not Applicable
Completed
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Registration Number
- NCT01039558
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
We will estimate the responses of lansoprazole and ecabet sodium combination therapy and compare with lansoprazole and placebo therapy in patients who need additional therapy after standard proton pump inhibitor treatment for 4week or more in recurrent gastroesophageal reflux disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- age 19-75 years
- patients with typical gastroesophageal symptom or erosive reflux esophagitis on gastroduodenoscopy
- patients with recurrent gastroesophageal symptom after standard proton pump inhibitor treatment for 4 weeks or more
Exclusion Criteria
- patients with gastric ulcer or duodenal ulcer
- patients with gastric cancer or esophageal cancer
- pregnant or postpartum women
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description lansoprazole + ecabet sodium ecabet sodium - lansoprazole + placebo placebo - lansoprazole + ecabet sodium lansoprazole - lansoprazole + placebo lansoprazole -
- Primary Outcome Measures
Name Time Method We will compare the summations of symptoms score and calculate the response rate after 4 weeks and 8 weeks
- Secondary Outcome Measures
Name Time Method the global response of treatment after 8 weeks
Trial Locations
- Locations (1)
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of